1,572
Participants
Start Date
August 10, 2021
Primary Completion Date
April 27, 2024
Study Completion Date
April 27, 2024
Pharmacogenetic testing
Genetic testing of CYP2D6 and CYP2C19
Clinical decisions support
Prescribing recommendations to the provider based on the pharmacogenetic testing results
Icahn School of Medicine at Mount Sinai, New York
The Institute for Family Health, New York
Nemours Children's Health System, Wilmington
Duke University Medical Center, Durham
Nemours Children's Health System, Jacksonville
University of Florida - Jacksonville, Jacksonville
University of Florida - Gainesville, Gainesville
Nemours Children's Health System, Orlando
Meharry Medical College, Nashville
Nashville General Hospital, Nashville
Vanderbilt University Medical Center, Nashville
Eskenazi Health, Indianapolis
Indiana University, Indianapolis
Sanford Health, Fargo
Lead Sponsor
National Human Genome Research Institute (NHGRI)
NIH
University of Florida
OTHER
Vanderbilt University Medical Center
OTHER
Indiana University School of Medicine
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Duke University
OTHER